

Yasser M Fouad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1432034/publications.pdf>

Version: 2024-02-01

54
papers

3,989
citations

393982

19
h-index

174990

52
g-index

55
all docs

55
docs citations

55
times ranked

3794
citing authors

#	ARTICLE	IF	CITATIONS
1	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020, 73, 202-209.	1.8	2,171
2	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	8.2	330
3	What's in a name? Renaming "NAFLD" to "MAFLD". <i>Liver International</i> , 2020, 40, 1254-1261.	1.9	212
4	Ineffective Esophageal Motility: The Most Common Motility Abnormality in Patients With Gerd-Associated Respiratory Symptoms. <i>American Journal of Gastroenterology</i> , 1999, 94, 1464-1467.	0.2	165
5	Global multi-stakeholder endorsement of the MAFLD definition. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 388-390.	3.7	135
6	Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 57-64.	3.7	110
7	Hepato-cardiac disorders. <i>World Journal of Hepatology</i> , 2014, 6, 41.	0.8	106
8	History of Nonalcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5888.	1.8	74
9	The NAFLD"MAFLD debate: Eminence vs evidence. <i>Liver International</i> , 2021, 41, 255-260.	1.9	64
10	Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists. <i>Journal of Hepatology</i> , 2021, 74, 1254-1256.	1.8	48
11	Oesophageal motility defects associated with nocturnal gastro-oesophageal reflux on proton pump inhibitors. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 1467-1471.	1.9	47
12	The sub-Saharan Africa position statement on the redefinition of fatty liver disease: From NAFLD to MAFLD. <i>Journal of Hepatology</i> , 2021, 74, 1256-1258.	1.8	39
13	The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 838-844.	1.9	36
14	Cystatin C: a predictor of hepatorenal syndrome in patients with liver cirrhosis. <i>Hepatology International</i> , 2011, 5, 927-933.	1.9	32
15	Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 674-679.	1.9	30
16	Barrett's esophagus: Prevalence and risk factors in patients with chronic GERD in Upper Egypt. <i>World Journal of Gastroenterology</i> , 2009, 15, 3511.	1.4	30
17	Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience. <i>Gut</i> , 2017, 66, 2008-2012.	6.1	28
18	Capturing patient experience: A qualitative study of change from NAFLD to MAFLD real-time feedback. <i>Journal of Hepatology</i> , 2021, 74, 1261-1262.	1.8	28

#	ARTICLE	IF	CITATIONS
19	Cochlear implantation under conscious sedation with local anesthesia; Safety, Efficacy, Costs, and Satisfaction. <i>Cochlear Implants International</i> , 2017, 18, 297-303.	0.5	24
20	MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1080-1089.	1.9	19
21	Clinical significance and diagnostic value of serum dickkopf-1 in patients with hepatocellular carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1133-1137.	0.6	16
22	Diagnostic Performance of Multidetector Computed Tomography (MDCT) in Diagnosis of Sinus Variations. <i>Polish Journal of Radiology</i> , 2017, 82, 713-725.	0.5	15
23	Effectiveness of 8-week sofosbuvir/ledipasvir in the adolescent chronic hepatitis C-infected patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1004-1009.	0.8	15
24	The paradigm shift from <scp>NAFLD</scp> to <scp>MAFLD</scp>: A global primary care viewpoint. <i>Liver International</i> , 2022, 42, 1259-1267.	1.9	15
25	The <scp>NAFLD&MAFLD</scp> debate: Is there a Consensus&Consensus methodology?. <i>Liver International</i> , 2022, 42, 742-748.	1.9	15
26	Is irritable bowel syndrome associated with chronic hepatitis C?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1285-1288.	1.4	14
27	Incidence and risk factors of retinopathy in Egyptian patients with chronic hepatitis C virus treated with pegylated interferon plus ribavirin. <i>International Journal of Infectious Diseases</i> , 2012, 16, e67-e71.	1.5	14
28	A randomized trial of 24 versus 48 weeks of peginterferon a-2a plus ribavirin in Egyptian patients with hepatitis C virus genotype 4 and rapid viral response. <i>Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation</i> , 2012, 33, 112-117.	0.0	14
29	Effects of sofosbuvir/ledipasvir therapy on chronic hepatitis C virus genotype 4, infected children of 3&6 years of age. <i>Liver International</i> , 2020, 40, 319-323.	1.9	13
30	Chronic hepatitis C-associated thrombocytopenia: aetiology and management. <i>Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation</i> , 2013, 34, 58-67.	0.0	13
31	The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. <i>Saudi Journal of Gastroenterology</i> , 2022, 28, 3.	0.5	12
32	Hepatitis C virus (genotype 4)-associated mixed cryoglobulinemia vasculitis: effects of antiviral treatment. <i>Hepatology International</i> , 2012, 6, 606-612.	1.9	11
33	Hematopoietic stem cell mobilization into the peripheral circulation in patients with chronic liver diseases. <i>Journal of Digestive Diseases</i> , 2012, 13, 571-578.	0.7	10
34	Predictors for Severity of SARS-CoV-2 Infection Among Healthcare Workers. <i>Journal of Multidisciplinary Healthcare</i> , 2021, Volume 14, 2973-2981.	1.1	10
35	Bile aspiration cytology in diagnosis of bile duct carcinoma: factors associated with positive yields. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2012, 19, 370-378.	1.4	9
36	Quality of Life after Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Compared with Transcatheter Arterial Chemoembolization alone. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 1255-1261.	0.5	8

#	ARTICLE	IF	CITATIONS
37	Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 374-382.	0.7	8
38	Arabic Association for the Study of Diabetes and Metabolism (AASD) endorsing the MAFLD definition of fatty liver disease. <i>Journal of Hepatology</i> , 2021, , .	1.8	6
39	Detection of hepatitis C virus core antigen as an alternative method for diagnosis of hepatitis C virus infection in blood donors negative for hepatitis C virus antibody. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1348-1351.	0.8	5
40	Management of liver disease patients in different clinical situations during COVID-19 pandemic. <i>Egyptian Liver Journal</i> , 2021, 11, 21.	0.3	5
41	Clinical Significance of Annexin A4 as a Biomarker in the Early Diagnosis of Hepatocellular Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 2661-2665.	0.5	4
42	MAFLD Not NAFLD is Associated with Impairment of Health-related Quality of Life. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 4-5.	0.7	4
43	Predictors of mortality in cases of thermal burns admitted to Burn Unit, Ain Shams University Hospitals, Cairo. <i>Journal of Clinical Forensic and Legal Medicine</i> , 2019, 67, 19-23.	0.5	3
44	Treatment of Chronic Hepatitis C in Adolescent Patients With Positive HBsAg or With Occult Hepatitis B: Is the Risk of Hepatitis B Reactivation Significant?. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, 11-15.	1.1	3
45	Renal duplex Doppler ultrasound in patients with HCV related liver cirrhosis. <i>Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation</i> , 2009, 30, 213-8.	0.0	3
46	Healthcare Providersâ€™ Perspective about the Use of Telemedicine in Egypt: A National Survey. <i>International Journal of Telemedicine and Applications</i> , 2022, 2022, 1-8.	1.1	3
47	Retreatment of chronic hepatitis C virus genotype-4 patients after non-structural protein 5A inhibitors' failure: efficacy and safety of different regimens. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 440-446.	0.8	2
48	The change from NAFLD to MAFLD expands fatty liver information flow. <i>Hepatology Research</i> , 2022, 52, 488-489.	1.8	2
49	One not like the other: The weakness of the blood sugar-MAFLD analogy. <i>Journal of Hepatology</i> , 2022, 76, 482-484.	1.8	1
50	Revised Nomenclature for Fatty Liver Disease: Cutting through the Confusion. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 1-2.	0.7	1
51	Letter to the editor: Apples should be compared with apples. <i>Hepatology</i> , 2022, 76, E101-E101.	3.6	1
52	Letter to the Editor: Metabolically healthy obese MAFLD: Are they truly healthy?. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	2.4	1
53	The EMRG Consortium: a gate to identify the burden of metabolic (dysfunction)-associated fatty liver disease in Egypt. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882110546.	1.4	0
54	Dose-Dependent Ivermectin Effect on COVID-19 Polymerase Chain Reaction Status. <i>American Journal of Therapeutics</i> , 2024, 31, e72-e81.	0.5	0